Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Buy
51
EVH Quote, Financials, Valuation and Earnings
Last price:
$11.67
Seasonality move
:
11.55%
Day range:
$11.22 - $11.49
52-week range:
$7.06 - $33.63
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.55x
P/B ratio:
1.44x
Volume:
1.6M
Avg. volume:
2.8M
1-year change:
-47.33%
Market cap:
$1.3B
Revenue:
$2.6B
EPS (TTM):
-$1.23
Analysts' Opinion
-
Consensus RatingEvolent Health has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.08, Evolent Health has an estimated upside of 31.79% from its current price of $11.44.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 21.33% downside risk from its current price of $11.44.
Fair Value
-
According to the consensus of 10 analysts, Evolent Health has 31.79% upside to fair value with a price target of $15.08 per share.
EVH vs. S&P 500
-
Over the past 5 trading days, Evolent Health has overperformed the S&P 500 by 1.27% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Evolent Health does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Evolent Health revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Evolent Health reported revenues of $483.6M.
Earnings Growth
-
Evolent Health has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Evolent Health reported earnings per share of -$0.63.
Enterprise value:
1.9B
EV / Invested capital:
--
Price / LTM sales:
0.55x
EV / EBIT:
--
EV / Revenue:
0.80x
PEG ratio (5yr expected):
-0.99x
EV / Free cash flow:
-197.10x
Price / Operating cash flow:
11.17x
Enterprise value / EBITDA:
58.83x
Gross Profit (TTM):
$365.7M
Return On Assets:
-4.25%
Net Income Margin (TTM):
-4.54%
Return On Equity:
-10.73%
Return On Invested Capital:
-6.52%
Operating Margin:
0%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $1.5B | $2.2B | $2.4B | $639.7M | $483.6M | |
| Gross Profit | $356.5M | $447.4M | $365.7M | $104.1M | $102.5M | |
| Operating Income | -$24.9M | -$23.8M | -$9.6M | -$4.5M | $4K | |
| EBITDA | -$38.5M | $40M | $32.6M | $18.8M | -$28.7M | |
| Diluted EPS | -$0.38 | -$1.25 | -$1.23 | -$0.22 | -$0.63 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $508.3M | $463.4M | $476M | $669.2M | $727.9M | |
| Total Assets | $1.3B | $1.3B | $2.6B | $2.6B | $2.7B | |
| Current Liabilities | $414.5M | $382.5M | $457.6M | $659M | $739.1M | |
| Total Liabilities | $688.3M | $727.9M | $1.3B | $1.6B | $1.7B | |
| Total Equity | $617.3M | $611.2M | $1.3B | $1B | $935.5M | |
| Total Debt | $228.7M | $282.6M | $632.3M | $597.9M | $819.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $37.9M | $155.5M | $18.4M | $4.9M | $4.6M | |
| Cash From Investing | -$670.9M | -$30.3M | -$66.3M | -$9.7M | -$13.1M | |
| Cash From Financing | $562.6M | -$83.5M | $92.4M | $14.9M | $107.9M | |
| Free Cash Flow | -$993K | $130.4M | -$9.7M | -$438K | -$4M | |
EVH
Sector
Market Cap
$1.3B
$34.4M
Price % of 52-Week High
34.02%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-47.33%
-37.36%
Beta (5-Year)
1.015
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
-17.97%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$11.41
200-day SMA
Sell
Level
$12.78
Bollinger Bands (100)
Buy
Level
8.43 - 10.65
Chaikin Money Flow
Sell
Level
-777.1K
20-day SMA
Buy
Level
$10.89
Relative Strength Index (RSI14)
Buy
Level
66.34
ADX Line
Sell
Level
22.38
Williams %R
Neutral
Level
-40.9836
50-day SMA
Buy
Level
$9.52
MACD (12, 26)
Buy
Level
3.10
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
1.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.9768)
Sell
CA Score
(Annual)
Level (-0.6247)
Sell
Beneish M-Score
(Annual)
Level (-2.2091)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.5004)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Stock Forecast FAQ
In the current month, EVH has received 9 Buy ratings 1 Hold ratings, and 0 Sell ratings. The EVH average analyst price target in the past 3 months is $15.08.
-
Where Will Evolent Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Evolent Health share price will rise to $15.08 per share over the next 12 months.
-
What Do Analysts Say About Evolent Health?
Analysts are divided on their view about Evolent Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Evolent Health is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is Evolent Health's Price Target?
The price target for Evolent Health over the next 1-year time period is forecast to be $15.08 according to 10 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is EVH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Evolent Health is a Buy. 9 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EVH?
You can purchase shares of Evolent Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Evolent Health shares.
-
What Is The Evolent Health Share Price Today?
Evolent Health was last trading at $11.67 per share. This represents the most recent stock quote for Evolent Health. Yesterday, Evolent Health closed at $11.44 per share.
-
How To Buy Evolent Health Stock Online?
In order to purchase Evolent Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 6.34% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is up 0.79% over the past day.
Sell
42
VLCN alert for Jul 17
Volcon [VLCN] is up 201.38% over the past day.
